Briacell Therapeutics Corp BCT.TO is expected to show no change in quarterly revenue when it reports results on June 12 (estimated) for the period ending April 30 2025
LSEG's mean analyst estimate for Briacell Therapeutics Corp is for a loss of $1.12 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 52.1% in the last three months.
Wall Street's median 12-month price target for Briacell Therapeutics Corp is $225.00, above its last closing price of $3.45.
This summary was machine generated March 14 at 20:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.